Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
KELOWNA, BC - Lexaria Bioscience Corp. (NASDAQ:LEXX), a small-cap biotech company with a market capitalization of $16.23 million, announced Thursday that its Contract Research Organization has completed the last patient last visit milestone in its Phase 1b glucagon-like peptide-1 (GLP-1) study in Australia. The company’s stock, currently trading near its 52-week low of $0.83, has shown impressive revenue growth of approximately 50% over the last twelve months, according to InvestingPro data.
The study, which involved 126 overweight, obese, pre- or type 2 diabetic patients across five study arms, is now moving into the laboratory analysis phase. During this stage, thousands of collected samples are being processed and recorded, with Lexaria remaining blinded to the data until database work is completed. The company maintains a strong financial position to support its research activities, with InvestingPro analysis showing a healthy current ratio of 3.9 and more cash than debt on its balance sheet.
"We are delighted that this important milestone has been achieved on schedule, concluding all patient dosing and clinical testing in our Study," said John Docherty, Lexaria’s President and CSO.
The company previously released partial 8-week interim results showing positive safety and tolerability outcomes, particularly noting reductions in gastrointestinal adverse events compared to the Rybelsus® control arm.
The study evaluated various formulations of Lexaria’s DehydraTECH drug delivery platform with GLP-1 medications. Four arms tested different DehydraTECH formulations, including combinations with CBD, pure semaglutide, and tirzepatide, while the fifth arm served as a control using Rybelsus® tablets.
Unlike traditional GLP-1 treatments that require injections, all doses in this study were administered orally via tablet or capsule, aligning with Lexaria’s goal of moving away from injectable delivery methods.
The study aims to determine whether DehydraTECH-processed medications are safe over the 12-week duration, if they can match or outperform existing formulations, and whether they demonstrate improved outcomes in weight loss, blood sugar control, and reduced side effects.
Final results from the study are projected to be available during the fourth quarter of 2025, according to the company’s press release statement. For investors interested in deeper analysis of Lexaria’s financial health and growth prospects, InvestingPro offers additional insights through its comprehensive set of financial metrics and 10 exclusive ProTips that can help evaluate the company’s investment potential.
In other recent news, Lexaria Bioscience Corp. has completed a significant milestone in its Phase 1b GLP-1 study in Australia, marking the end of patient dosing and clinical testing. The company is now proceeding to the sample and data analysis phase. H.C. Wainwright has adjusted its price target for Lexaria Bioscience, lowering it from $5.00 to $4.00, while maintaining a Buy rating. This adjustment comes after Lexaria announced interim results from its ongoing Phase 1b GLP-1-H24-4 study, which includes different arms focusing on DehydraTECH-semaglutide, DehydraTECH-tirzepatide, and Rybelsus.
Additionally, Lexaria Bioscience has reported that its DehydraTECH technology can reduce side effects in leading GLP-1 drugs such as semaglutide, tirzepatide, and liraglutide. This development could address the high discontinuation rates due to gastrointestinal issues among GLP-1 users. The company has also expanded its patent portfolio to 50 with new international patents, including one in Australia for epilepsy treatment methods, which will extend until 2044. Furthermore, H.C. Wainwright previously lowered Lexaria’s stock price target from $7.00 to $5.00 after positive partial results from a study comparing DehydraTECH-processed liraglutide to Saxenda injections.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.